# Mapping B-cell Biology Across the Cardiovascular Territories of Giant Cell Arteritis: Towards a New Therapeutic Approach (RituxiMAP GCA)

> **NCT07269938** · — · NOT_YET_RECRUITING · sponsor: **University of Edinburgh** · enrollment: 30 (estimated)

## Conditions studied

- Giant Cell Arteritis (GCA)

## Interventions

- **DIAGNOSTIC_TEST:** Zirconium Zr 89 labelled rituximab

## Key facts

- **NCT ID:** NCT07269938
- **Lead sponsor:** University of Edinburgh
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2029-04
- **Final completion:** 2029-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07269938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07269938, "Mapping B-cell Biology Across the Cardiovascular Territories of Giant Cell Arteritis: Towards a New Therapeutic Approach (RituxiMAP GCA)". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT07269938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*